PUBLISHER: IMARC | PRODUCT CODE: 1451477
PUBLISHER: IMARC | PRODUCT CODE: 1451477
The global OTC artificial tears market size reached US$ 5.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.8 Billion by 2032, exhibiting a growth rate (CAGR) of 4.58% during 2024-2032.
Over the Counter (OTC) artificial tears are eye drops that are used for lubricating eyes and providing relief from pain, discomfort, burning, redness, photophobia and irritation in the eyes. They are manufactured using dextran, glycerin, propylene glycol, hydroxypropyl methylcellulose (HPMC) and carboxymethylcellulose. Artificial tears are widely used for the treatment of dry eyes, which is a medical condition when sufficient moisture or lubrication is not generated on the conjunctiva, cornea or entire surface of the eye. OTC artificial tears are biocompatible and aid in stabilizing the tear film, promoting healing and minimizing tear evaporation. In addition to this, OTC artificial tears are also available in ointment, spray, emulsion, solution and gel forms that are highly convenient use.
The rising geriatric population that is prone to chronic eye-related disorders is one of the key factors driving the growth of the market. Due to the increasing prevalence of dry eye syndrome (DES), diabetes and nutritional deficiencies, there is a rising demand for OTC artificial tears to provide immediate relief from discomfort in the eyes. Additionally, the increasing utilization of electronics, such as smartphones, televisions (TVs) and laptops, leading to excessive screen time and eye fatigue, is positively impacting the adoption of OTC artificial tears. Various product innovations, such as the development of variants fortified with blink-activated coatings, are providing a thrust to the market growth. These coatings provide ocular hydration to patients suffering from evaporative dry eye syndrome. In line with this, the widespread product adoption with contact lenses to facilitate the flow of oxygen to the cornea and prevent dryness on the surface of the eyes is favoring the market growth. Other factors, including rising levels of pollution, especially in the urban regions, along with the increasing health consciousness among the masses, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global OTC artificial tears market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, container type, formulation, application and distribution channel.
Solution
Ointment
Emulsion
Gel
Spray Solution
Suspensions
Plastic Single Dose Container
Plastic Multi-Dose Container
Others
Preservative Based
Non-Preservative Based
Dry Eye Syndrome
Allergies
Infections
UV and Blue Light Protection
Contact Lens Moisture Retention
Others
Hospital Pharmacies
Drug Store and Retail Pharmacies
Online Pharmacies
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Johnson & Johnson, Nicox S.A., OASIS Medical, OCuSOFT Inc., Santen Pharmaceutical Co. Ltd., Similasan Corporation, Sun Pharmaceutical Industries Ltd. and URSAPHARM Arzneimittel GmbH.